Board of Directors

Peter Høngaard Andersen

Chairman of the Board, Scandion Oncology and member of Board of Directors since June 2019

Education: Holds degrees in Chemistry, Biochemistry and Medicine

Background: Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and Corporate Patents. Founder of Innovation Fund Denmark and Managing Director until May 2019 Chairing Innovative Medicines Initiative (IMI) from 2009 – 2014. Co-founder of e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.

Other ongoing assignments: Board member in Immunovia AB, Monsenso A/S, Venture Partner in Ysios Capital and member of the Scientific Advisory Board in Eir Ventures.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
53,065 shares and 80,377 warrants


Jørgen Bardenfleth

Vice-Chairman of the Board, Scandion Oncology and member of Board of Directors since 2018

Education: MSc in Engineering from the Technical University of Denmark (DTU) and a MBA from the University of California, Los Angeles

Background: Professional board member since 2013, prior General Manager in high tech companies Microsoft, Intel and Hewlett-Packard 1989-2013. Board and steering committee work in Danish Science Parks, Innovationsfonden and Innovation Technology consortias.

Other ongoing assignments: Chairman of the Board in Lyngsoe Systems, Dubex, Symbion, Medical Technology Innovation Consortium (MTIC), COBIS and Impero. Board member in Bizbrains, Minerva, Accelerace, BLOXHUB (vice chair), CataCap et al.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
410,629 shares and 53,585 warrants (Partly owned via Lioneagle ApS)


Carl Borrebaeck

Member of the Board of Directors since 2017

Education: D.Sc.

Background: Professor Lund University. Co-founder of Immunovia AB, Senzagen AB, BioInvent International AB, Alligator Bioscience AB.

Other ongoing assignments: Chairman of the Board in Immunovia AB, SenzaGen AB and PainDrainer AB. Board member in PainDrainer AB.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
112,165 shares and 26,792 warrants (Partly owned via CB Ocean Capital AB)


Christian Vinding Thomsen

Member of the Board of Directors since 2017

Education: Holds a law degree (Cand.jur.) from the University of Copenhagen’s Faculty of Law

Background: Partner, Attorney-at-law, BKH Law P/S. Previously, Partner, attorney-at-law, Bech-Bruun . Life Science specialist (M&A and regulatory).

Other ongoing assignments: Chairman of the board in KT Stålindustri A/S and vice chairman at Medicoindustriens Udredningspanel. Board member in Reponex Pharmaceuticals A/S, AKI Therapeutics ApS, RepoCeuticals A/S and the Danish Life Science Law Association.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
26,792 warrants


Thomas Feldthus

Member of the Board of Directors since 2018

Education: MSc in Engineering from the Technical University of Denmark (DTU), MSc in Management and Economics from the University of London, and a Fellow of the London Business School Sloan Program

Background: Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.

Other ongoing assignments: CEO of Fertilizer Invest ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
18,182 shares and 26,792 warrants


Martin Møller

Member of the Board of Directors since May 2021

Education: MA in comparative literature

Background: Worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.

Other ongoing assignments: Board member in Immunovia AB

Independence: Independent in relation to both the Company and executive management as well as larger shareholders

Scandion Oncology shares and warrants
None


Bo Rode Hansen

President & CEO and member of the Board of Directors since May 2020 

Education: MSc, Ph.D., MBA

Background: Previously, President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (acquired by Roche).

Other ongoing assignments: Advisor for Novo Seeds

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.

Scandion Oncology shares and warrants
40,400 shares and 1,071,688 warrants


Annie Rasmussen

Member of the Board of Directors (employee representative) since 2020

Education: RN, Master of Public Health

Background: Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982.

Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operations Oncology Venture A/S. Founder of Health- CreationDK and CancerGuidesDK.

Other ongoing assignments: Board member of North Star Group A/S.

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.

Scandion Oncology shares and warrants
18,795 shares and 53,585 warrants

Pipeline

Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance. 

Clinical Trials

Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Investors

Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.

We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.